Mechanisms of Muscle Weakness Associated with Bone Metastases

Cancer-associated muscle dysfunction represents a deadly clinical problem, with ca. 80% mortality together with an increased toxicity from cancer treatment.. The normal bone remodeling might be disrupted by tumor cells that metastasize to bone in certain stages of cancer, which results in increased morbidity including muscle weakness. The reason for that muscle weakness might be attributed to the reduction on muscle mass or the reduction of muscle function. In fact, it has been demonstrated that in advanced cancers, it is probably caused by a combination of reductions, quantity and quality of muscle. This review focuses on the mechanisms that bone metastases promote skeletal muscle weakness.

[1]  A. Molfino,et al.  Perioperative nutritional intervention: a way to improve long-term outcomes , 2016, Nature Reviews Clinical Oncology.

[2]  R. Lovering,et al.  Critical Role of Intracellular RyR1 Calcium Release Channels in Skeletal Muscle Function and Disease , 2016, Front. Physiol..

[3]  Wenjun Xie,et al.  Excess TGF-β mediates muscle weakness associated with bone metastases in mice , 2015, Nature Medicine.

[4]  S. Anker,et al.  Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014 , 2014, Journal of cachexia, sarcopenia and muscle.

[5]  J. Frank,et al.  Structure of a mammalian ryanodine receptor , 2014, Nature.

[6]  G. Ávila,et al.  Ryanodine receptors as leak channels. , 2014, European journal of pharmacology.

[7]  Arash Salmaninejad,et al.  Roles of oxidative stress in the development and progression of breast cancer. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[8]  F. Sotgia,et al.  Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. , 2014, Seminars in oncology.

[9]  V. Baracos,et al.  Understanding the mechanisms and treatment options in cancer cachexia , 2013, Nature Reviews Clinical Oncology.

[10]  T. Moliné,et al.  Oxidative stress and cancer: An overview , 2013, Ageing Research Reviews.

[11]  J. Bartek,et al.  IL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine ‘Bystander senescence’ , 2012, Aging.

[12]  D. Glass,et al.  Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.

[13]  Raynoo Thanan,et al.  Role of Nitrative and Oxidative DNA Damage in Inflammation-Related Carcinogenesis , 2012, Journal of biomedicine & biotechnology.

[14]  J. Stamler,et al.  Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4 , 2011, Proceedings of the National Academy of Sciences.

[15]  T. Shiomi,et al.  Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. , 2011, Cell metabolism.

[16]  Michael D. Schneider,et al.  NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart , 2010, Proceedings of the National Academy of Sciences.

[17]  A. Verkhratsky,et al.  An intelligent sarco-endoplasmic reticulum Ca2+ store: release and leak channels have differential access to a concealed Ca2+ pool. , 2010, Cell calcium.

[18]  A. Marks,et al.  Fixing ryanodine receptor Ca leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. , 2010, Drug discovery today. Disease mechanisms.

[19]  S. Matecki,et al.  Hypernitrosylated ryanodine receptor/calcium release channels are leaky in dystrophic muscle , 2009, Nature Medicine.

[20]  S. Reiken,et al.  Remodeling of ryanodine receptor complex causes “leaky” channels: A molecular mechanism for decreased exercise capacity , 2008, Proceedings of the National Academy of Sciences.

[21]  A. Saxena,et al.  Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation , 2007, British journal of biomedical science.

[22]  P. Delmas,et al.  Bone quality--the material and structural basis of bone strength and fragility. , 2006, The New England journal of medicine.

[23]  S. Reiken,et al.  Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Peluso,et al.  Skeletal muscle metabolism in physiology and in cancer disease , 2003, Journal of cellular biochemistry.

[25]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[26]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[27]  R. Coleman Skeletal complications of malignancy , 1997, Cancer.

[28]  J. Yingling,et al.  Development of TGF-beta signalling inhibitors for cancer therapy. , 2004, Nature reviews. Drug discovery.